Fulcrum Therapeutics Inc (FULC) - News Archive

Fulcrum Therapeutics Expands Workforce Through Inducement Stock Option Grants: A Strategic Move Compliant with Nasdaq Listing RulesFulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company he...

CAMBRIDGE, Mass. April 11, 2025 Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to enhance the lives of patients with genetically defined rare...

Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a prominent player in the biopharmaceutical industry, is currently under investigation by Bronstein, Gewirtz & Grossman, LLC. This development has sent ripples of concern throu...

: The pharmaceutical sector is often characterized by rapid fluctuations in stock prices, driven by a multitude of factors including clinical trial outcomes, regulatory developments, and market dynamics. Fulcrum Therape...

NEW YORK, Sept. 13, 2024 Investors holding securities of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) should be aware of an important development. Bronstein, Gewirtz & Grossman, LLC, a renowned law firm specializing in sec...

nnFulcrum Therapeutics Reports Disappointing Phase 3 Results for Losmapimod in FSHD: Financial Ramifications and Stock Performance AnalysisnnFulcrum Therapeutics Inc. a clinical-stage biopharmaceutical company focused o...

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company dedicated to developing small molecules for patients with rare genetic diseases, recently announced the granting of non-statutory sto...

Fulcrum Therapeutics Grants Stock Options to New Employees: A Strategic Move to Enhance Rare Disease Treatment DevelopmentFulcrum Therapeutics, a leading biopharmaceutical company dedicated to improving the lives of pat...

The realm of medical developments related to Facioscapulohumeral Muscular Dystrophy (FSHD) is on the brink of a paradigm shift. The latest milestone in this healthcare journey is the recently announced collaboration and...

Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic disorder characterized by progressive muscle weakness and atrophy. Current treatment options for FSHD are limited, necessitating the discovery of innovativ...

Fulcrum Therapeutics Continues to Reward Talent with Inducement GrantsIn an effort to attract top talent and retain key executives, Fulcrum Therapeutics, a leading biopharmaceutical company specializing in rare genetic...

CAMBRIDGE, Mass., Dec. 07, 2023 - Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with genetically defined rare diseases, has announced...